Literature DB >> 22283890

Recurrence after successful treatment among patients with multidrug-resistant tuberculosis.

J Lee1, H-J Lim, Y-J Cho, Y S Park, S-M Lee, S-C Yang, C-G Yoo, Y W Kim, S K Han, J-J Yim.   

Abstract

A retrospective review was conducted of patients with multidrug-resistant tuberculosis (MDR-TB) to elucidate the rate of recurrence after successful treatment. Of 123 MDR-TB patients, 90 were declared as 'cured' or 'treatment completed' after individualised treatment; four (4.4%) experienced recurrence. All patients with recur- rent MDR-TB were documented as 'treatment completed' after treatment. Recurrence of MDR-TB is possible after successful treatment, particularly among those documented as 'treatment completed'.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22283890     DOI: 10.5588/ijtld.11.0098

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  5 in total

1.  Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.

Authors:  J S Cavanaugh; B Y Kazennyy; M L Nguyen; E V Kiryanova; E Vitek; T M Khorosheva; E Nemtsova; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012-06-11       Impact factor: 2.373

2.  Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence.

Authors:  Molly F Franke; Sasha C Appleton; Carole D Mitnick; Jennifer J Furin; Jaime Bayona; Katiuska Chalco; Sonya Shin; Megan Murray; Mercedes C Becerra
Journal:  Clin Infect Dis       Date:  2012-12-07       Impact factor: 9.079

3.  Recurrence after Successful Treatment of Multidrug-Resistant Tuberculosis in Taiwan.

Authors:  Meng-Yu Chen; Yi-Chun Lo; Wan-Chin Chen; Kwei-Feng Wang; Pei-Chun Chan
Journal:  PLoS One       Date:  2017-01-26       Impact factor: 3.240

4.  Cost-effectiveness of bedaquiline in MDR and XDR tuberculosis in Italy.

Authors:  Luigi R Codecasa; Mondher Toumi; Anna D'Ausilio; Andrea Aiello; Francesco Damele; Roberta Termini; Alessia Uglietti; Robert Hettle; Giorgio Graziano; Saverio De Lorenzo
Journal:  J Mark Access Health Policy       Date:  2017-02-17

5.  Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.

Authors:  Daniel Wirth; Ramesh Dass; Robert Hettle
Journal:  BMC Health Serv Res       Date:  2017-03-08       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.